NEW YORK (GenomeWeb) – Rosetta Genomics said today that it has agreed to sell its PersonalizeDx unit to healthcare business group Pragmin Prognosis for $2.9 million in cash.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.